By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC Building the right team is a popular topic because it is difficult and a company’s success hinges on it. In a cash-crunched biotech The post A Delicate Balance: Building NewCos with Jacks of All Trades and Utility Players appeared first on LifeSciVC.| LifeSciVC
By Ankit Mahadevia, founder and board director of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC Biotech leaders love talking about ‘margin of safety’—but what if the safety nets we build are just illusions? In The Intelligent The post The Intelligent Entrepreneur: Real and Illusory Margins of Safety in Company Building appeared first on LifeSciVC.| LifeSciVC
By Cody Tranbarger, EIR at Atlas Venture, as part of the From The Trenches feature of LifeSciVC As the biotech industry trudges through its fourth consecutive year of middling performance and sluggish capital markets, corporate governance has become a salient The post A [Prime]r on Stock Option Repricing in Biotech appeared first on LifeSciVC.| LifeSciVC
By Gerry Harriman, CSO and co-founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC As scientists, we are accustomed to learning something new about targets (and the modulation thereof) that moves the field forward in The post A “Complex” Solution to a “Complex” Problem? Attacking KRASG12X Colorectal Cancer Through the CBM Signalosome appeared first on LifeSciVC.| LifeSciVC
By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC If you are a first-time founder who has heard the phrase “This isn’t a good time to be raising for X,” where X The post Best Practices for Pitching, Geared Towards First-Time Founders appeared first on LifeSciVC.| LifeSciVC
By Jason Campagna, CMO of Q32, as part of the From The Trenches feature of LifeSciVC In a recent essay, I argued that biotech is entering its strategic infrastructure moment, a shift from molecule-centric innovation to a layered capability stack The post Leadership in the Age of Stacks appeared first on LifeSciVC.| LifeSciVC
By Ram Aiyar, CEO of Korro Bio, as part of the From The Trenches feature of LifeSciVC It has been an extraordinary journey so far and one that continues to humble, inspire and motivate me every day. I’ve had the The post Building Korro Bio: A CEO’s Perspective on Innovation and Risk Management appeared first on LifeSciVC.| LifeSciVC
By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC It’s easy to jump on the ‘negative bandwagon’ these days when news in our world and industry is focused on doom & gloom. The post “We Got This”: Don’t Let Negativity Become a Self-fulfilling Prophecy appeared first on LifeSciVC.| LifeSciVC
Over 200 GLP1 obesity programs are in development today. More than 300 PD1/PDL1 cancer programs exist. Greater than 150 programs target each of CD19 and KRAS. Therapeutic crowding has ratcheted up the competitive intensity in biotech to new levels. While The post Biotech Wisdom Of The Crowds: Competition And Capitalism appeared first on LifeSciVC.| LifeSciVC
By Ankit Mahadevia, former CEO of Spero Therapeutics and Atlas alumni, as part of the From The Trenches of LifeSciVC I recently read Yuval Noah Hariri’s Nexus; what stuck with me was how a society uses information to create shared The post Information Flow In Growing Organizations: A Framework For Results appeared first on LifeSciVC.| LifeSciVC
By Cody Tranbarger, EIR at Atlas Venture, as part of the From The Trenches feature of LifeSciVC It’s an interesting time to be thinking about space. Just a few months ago, SpaceX captivated and inspired the world by catching a The post Boosters and Biologics: Is Space-Based Biomanufacturing Real? appeared first on LifeSciVC.| LifeSciVC
By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC Drug discovery and development is a long, and often fraught, journey – it typically takes more than a decade to progress from idea The post Frameworks for Decision-Making & Lessons Learned from “Failing Fast” appeared first on LifeSciVC.| LifeSciVC
The equity markets have collapsed in 2025, the IPO window is closed, the FDA is in turmoil, the NIH is being gutted… and it’s a great time to start new biotech companies. Why? Because there are so few being created The post Biotech Venture Creation: The Benefits Of Scarcity appeared first on LifeSciVC.| LifeSciVC
By Jason Campagna, CMO of Q32 Bio, as part of the From The Trenches feature of LifeSciVC We’re entering a phase shift in biotech—one that extends beyond molecules, pipelines, or even platforms. Tariff escalations, supply chain fractures, and a reassertion The post Strategic Infrastructure in a Fragmenting World: Biotech in the Transition Zone appeared first on LifeSciVC.| LifeSciVC
By Arthur Tzianabos, CEO of Lifordi Immunotherapeutics, as part of the From The Trenches feature of LifeSciVC Given everything going on in our world right now, I’ve been thinking a lot about the state of biotech innovation…particularly as we wrestle| LifeSciVC
“When the going gets tough, the tough get going” By Ram Aiyar, CEO of Korro Bio, as part of the From the Trenches feature of LifeSciVC. It has been quite a start to the 2025 year. The sentiment around biotech The post The Biotech Juggling Act: Keeping all the Balls in the Air appeared first on LifeSciVC.| LifeSciVC
By Ankit Mahadevia, serial biotech entrepreneur and former CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC I recently had an illuminating discussion with a seed-stage biotech Founder, who was reflecting after a hard and The post Pitfalls Of The Scarcity Mindset appeared first on LifeSciVC.| LifeSciVC
By Cody Tranbarger, EIR at Atlas Venture, as part of the From The Trenches feature of LifeSciVC For decades, muscular dystrophy has stubbornly persisted among the most intractable categories of human disease. Despite recent progress with AAV Gene Therapy and The post Dancing with the DGC: Structural Biology Meets Muscular Dystrophy appeared first on LifeSciVC.| LifeSciVC
By Jonathan Montagu, CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC In the perpetual and never-ending race by the healthcare sector to unearth new approaches and therapeutics to address disease, one area in which The post A New Wave of Therapeutic Innovation Through Targeting Transcription Factors appeared first on LifeSciVC.| LifeSciVC
By Aimee Raleigh, Principal at Atlas Venture, as part of the From The Trenches feature of LifeSciVC “It was the best of times, it was the worst of times…” Another JPM is behind us, and while much of the small The post A Tale of Two Sentiments: JPM 2025 appeared first on LifeSciVC.| LifeSciVC
